This research service provides an in-depth analysis of the global pharmaceutical contract manufacturing market with particular focus on the finished dose formulations such as solid, liquid and semi-solid, and injectable dose formulations. Segment analysis, trends and revenue forecast for the global, U.S. and European regions have been provided in detail. Strategic recommendations for the success of market participants have also been discussed.

1. Global Pharmaceutical Contract Manufacturing Market
Injectable Dose Formulations Will Likely Spur the Growth of CMOs
NC04-52
August 2013

2. Research Team
Aiswariya Chidambaram
Senior Research Analyst
Life Sciences
(9144) 6160-4249
AiswariyaC@frost.com
Lead Analyst

3. 3NC04-52
Scope and Segmentation
Geographic coverage
Global: United States, Europe (Germany, United Kingdom, France, Italy,
Spain, Scandinavia, and Benelux), and Rest of World (ROW)
Study period 2009–2017
Base year 2012
Forecast period 2013–2017
Monetary unit US Dollars
Conversion rate €1 = $1.31
Source: Frost & Sullivan

4. 4NC04-52
Market Segmentation
The pharmaceutical contract manufacturing market can be broadly divided into 3 main segments: solid
dose formulations, liquid and semi-solid dose formulations, and injectable dose formulations.
• Solid dose formulations comprise basic (tablets and capsules) and advanced (controlled-release), fast-
dissolving, and soft-gel, which are multi-active pharmaceutical ingredient (API) oral finished dose
formulations.
• Liquid and semi-solid dose formulations include nasal, nebulized, ophthalmic, otic, and topical
formulations, including sterile and non-sterile preparations.
• Injectable dose formulations are sterile preparations, including small- and large-volume parenterals.
Small-volume parenterals are of 2 types: cytotoxic and non-cytotoxic.
Solid Dose Formulations
Liquid and Semi-solid Dose
Formulations
Total Pharmaceutical Contract Manufacturing Market
Total Pharmaceutical Contract Manufacturing Market: Market Segmentation, Global, 2012
Injectable Dose
Formulations
Market Segmentation
Source: Frost & Sullivan

5. 5NC04-52
Segment Lifecycle Analysis
Injectable Dose Formulations
MaturityDevelopment Growth Decline Time
SegmentValue
Solid Dose Formulations
Injectable dose formulations is the
fastest growing segment, with a
projected growth rate of 12.2% in
2012, which is higher than the
overall pharmaceutical contract
manufacturing market. Increased
focus on cytotoxics, lyophilised
prefilled syringes, and
reformulation of existing products
is expected to drive the
remarkable success of injectables.
The liquid and semi-solid dose
formulations segment is
declining because of storage
and transportation issues, with
the major target group being the
paediatric population. Minimal
R&D is also carried out in this
segment.
Solid dose formulations is the
largest segment of the global
pharmaceutical contract
manufacturing market. Growth in
this segment is primarily attributed
to lower cost, ease of
manufacturing, patient compliance,
and the patent cliff.
Note: Bubble size represents market size.
Liquid and Semi-solid
Dose Formulations
Total Pharmaceutical Contract Manufacturing Market: Segment Lifecycle Analysis, Global, 2012
Source: Frost & Sullivan

6. 6NC04-52
Market Engineering Measurements
Market Stage
Growth
Market Revenue
$13.43 B
(2012)
Market
Penetration
Medium
(2012)
Market Nature
Fragmented
Market Size for
Last Year of
Study Period
$18.49 B
(2017)
Base Year
Market Growth
Rate
5.9%
Compound
Annual Growth
Rate
6.6%
(CAGR, 2012 - 2017)
Customer Price
Sensitivity
9
(scale:1 [low] to 10 [High])
Degree of
Technical
Change
8
(scale:1 [low] to 10 [High])
For a tabular version click here.
Market
Concentration
23.0%
Total Pharmaceutical Contract Manufacturing Market: Market Engineering Measurements,
Global, 2012
Market Overview
(% of market share held by top
3 companies)
Note: All figures are rounded. The base year is 2012. Source: Frost & Sullivan
Stable IncreasingDecreasing

7. 7NC04-52
Number of
Competitors
Nearly 450
(active market competitors in
2012)
Number of
Generic
Manufacturers
High
(none, low, medium, high)
Market Engineering Measurements (continued)
Competitor Overview
Number of
Companies that
Entered
< 10
(2012)
Additional Key Metrics
Average
Product
Development
Time
5–10 years
Stable IncreasingDecreasing
Industry
Capacity
Utilisation Rate
45.0%
(2012)
Note: All figures are rounded. The base year is 2012. Source: Frost & Sullivan

8. 8NC04-52
CEO’s Perspective
2
The pharmaceutical contract manufacturing
market is highly fragmented, and
consolidation is required to improve
profitability.
3
Thirty percent of existing participants could
exit the market due to pricing pressure and
low profit margins, mainly in the liquid and
semi-solid dose formulations segment.
4
Capturing projects at the early life-cycle
stage of products and a risk-sharing business
model can help build long-term strategic
relationships.
1
Lyophilisation and manufacturing of sterile
products such as cytotoxics will likely be
areas of growth potential, given the demand
for oncology and high-potency drugs.

9. 9NC04-52
Key Findings
• In 2012, the global pharmaceutical contract manufacturing market generated $13.43 billion in revenue.
The forecast shows a compound annual growth rate (CAGR) of 6.6% from 2012 to 2017.
o The injectable dose formulations segment will likely be the primary growth driver for outsourcing
throughout the forecast period.
• In 2012, solid dose formulations was the largest segment, constituting 49.8% of the total pharmaceutical
contract manufacturing market, and is projected to grow at a CAGR of 3.4% from 2012 to 2017.
o Generics will likely be a key growth driver for the solid dose formulations segment; however, this
segment will likely lose shares to the injectable dose formulations segment because of big pharma’s
shift in focus from small molecules to large molecules.
• Injectable dose formulations is the fastest growing segment and is projected to register a robust CAGR
of 13% from 2012 to 2017.
o Key growth drivers include increased pharmaceutical and biotechnological focus on complex disease
areas, trends in disease control, growth in emerging markets, the pharmaceutical patent cliff (several
blockbuster drugs losing patent protection), and reformulation of existing products.
o The major growth contributor is expected to be cytotoxics as both cancer research and the
development of new cancer therapies are driving growth in this area.
Source: Frost & Sullivan

10. 10NC04-52
• The liquid and semi-solid dose formulations segment is quite mature and expected to experience a
relatively lower CAGR of 2.5% from 2012 to 2017.
o Decreasing demand for liquid dose formulations is primarily attributed to transportation, storage, and
packaging issues associated with these formulations as well as lower returns compared to injectable
dose formulations manufacturing.
o The sterile liquid and semi-solid dose preparations, particularly nasal ophthalmic dose formulations,
are expected to experience strong growth; however, these preparations currently constitute a very
small segment of the market.
• Because of big pharma’s increased outsourcing, the pharmaceutical contract manufacturing market is
expected to show consistent growth. CMOs are striving to provide greater value proposition for clients
by engaging in the early life-cycle stage projects and establishing long-term relationships.
o To improve their value proposition to manufacturers, many CMOs are focusing on pre-clinical
development services and can transition from offering clinical services to offering commercial
manufacturing to integrate throughout the value chain of clients.
• Industry consolidation is on an increasing curve. The fragmented market nature will likely intensify
pricing pressure and drive down CMO revenues.
• Catalent Inc., Patheon Inc., and Aenova (with the acquisition of the Temmler group) are the top 3
market participants, constituting a combined share of 23% in the global pharmaceutical contract
manufacturing market.
Key Findings (continued)
Source: Frost & Sullivan

11. 11NC04-52
Defining CMO Trends in the Future
Topic Present (2012) Future Outlook (2022)
Key Areas
Outsourced
A majority of CMOs currently outsource
development activities such as formulations,
toxicity testing, fill and finish services, and
product characterization activities.
Outsourcing of crucial operations such as upstream and downstream
processes is likely in the interest of time, cost, and efficiency.
Capacity
Utilisation
The global industry capacity utilisation rate
is nearly 45%.
The global industry capacity utilisation rate is expected to increase 55 to
60% because of several blockbuster drugs coming out of patent, new
product launches, and more plant shut downs.
Role of Venture
Capital (VC) Firms
The lack of interest from VC firms to invest
in CMO space is because of poor
profitability and an unstable economic
climate.
VC investments may solidify when the economy gains more steam.
CMOs in emerging markets could be potential targets for investments.
Industry
Consolidation
Consolidation in the form of strategic
partnerships between CMOs,
pharmaceutical and biotech companies,
drug delivery companies, and technology
providers is on an increasing curve.
There will be greater consolidation and emphasis on core dose
formulations in the global CMO market. Thirty percent of current
participants will likely exit over the next 10 years because of intense
price competition and poor profit margins, particularly in liquid and semi-
solid dose formulations.
Favored
Destinations for
Outsourcing
Currently, the United States and Europe are
major markets for outsourcing of finished
dose formulations and sterile preparations,
while Asian CMOs are preferred
destinations for APIs, intermediates, and
generics.
Given the immense cost benefits, Asian CMOs such as in India, China,
and Singapore will likely emerge as favorable destinations, particularly
for solid dose formulations.
Business Model
Several CMOs focus on manufacturing
services as their core business segment.
Adherence to an integrated end-to-end business model offers value-
added services, thereby serving as a one-stop shop for customers.
How will your company meet the future needs of the industry?
Total Pharmaceutical Contract Manufacturing Market: Market Outlook, Global, 2012 and 2022
Source: Frost & Sullivan

12. 12NC04-52
New Market Opportunities
Unmet Needs
• An integrated, end-to-end business model on a
risk sharing basis with clients
• Instilling new capabilities and anticipating
capacity demand for careful outweighing of
benefits and risks
• Huge demand for next-generation biological
therapies such as vaccines, anti-cancer
therapies, gene therapies, specialized antibiotic
treatments, and recombinant proteins
Current Participant Strategies
• Repositioning product/service offerings to
enhance value proposition among clients and
building long-term strategic partnerships on a
risk-sharing basis
• Acquiring new capabilities and capacity
expansions by means of strategic partnerships
to fulfill global demand
• Increased focus on niche specialties such as
aseptic manufacturing of injectable dose
formulations to reap higher profit margins
Source: Frost & Sullivan

13. 13NC04-52
Key Companies to Watch
Patheon Inc.
• Patheon provides services to
more than 300 clients,
including the world’s 20
largest pharmaceutical
companies, 9 of the 20 largest
specialty pharmaceutical
companies, and 10 of the 20
largest biotech companies.
• Patheon has a strong track
record in the solid dose
formulations segment, with
one of the highest number of
solid dose drugs worldwide.
• Patheon has one of the
highest number of FDA new
drug approvals compared to
most other CMOs.
Aenova
• Aenova is one of the world’s
largest full-service providers
in the solid dose formulations
segment, with cutting-edge
technologies in the
production of a wide range of
tablets and capsules.
• Aenova experienced a
significant increase in market
shares after acquiring the
Temmler Group.
• Aenova acquired new
capabilities in products (liquid
and semi-solid dose
formulations) and services
(manufacturing of clinical trial
materials, logistics,
distribution, and licensing).
Baxter BioPharma Solutions
• Baxter is well known for its
proven expertise in parenteral
dose manufacturing, with
more than 1 billion sterile units
manufactured per year.
• Baxter was the first company
to introduce premixed drugs in
IV containers and the first
company to package its drugs
in IV containers.
• Baxter has an established
physician user base
worldwide, providing valuable
distribution channels to
expedite new product
launches combined with
strong sales and marketing
support services.
For additional information on companies, click here. Source: Frost & Sullivan

14. 14NC04-52
2
Given the highly fragmented market nature and intense competition, CMO providers
will likely adopt a differentiation strategy to reposition themselves among clients.
3
Investments and capacity expansions in the injectable dose formulations segment,
particularly cytotoxics manufacturing, are expected as they are anticipated to be the
most significant sources of revenue for the pharmaceutical contract manufacturing
industry.
1
Consolidation and an emphasis on core dose formulations will likely continue in the
pharmaceutical contract manufacturing market. Thirty percent of the current market
participants will likely exit over the next 10 years.
Executive Summary—3 Big Predictions
Source: Frost & Sullivan

15. 15NC04-52
Contents
Section Slide Number
Executive Summary 25
• Scope and Segmentation 26
• Market Segmentation 27
• Key Questions This Study Will Answer 28
• Market Engineering Measurements 29
• CEO’s Perspective 31
• Key Findings 32
• Key Companies to Watch 34
• Executive Summary—3 Big Predictions 35
• The Last Word—Discussion 36
Market Overview 39
• Market Segmentation 40
• Segmentation by Manufacturing Process 41
• Segmentation by Patent Exclusivity Status 42
• Global Market Perspective 43
• Defining CMO Trends in the Future 44

16. 16NC04-52
Contents (continued)
Section Slide Number
Competitive Playbook 45
• New Market Opportunities 46
• Key Merger, Acquisition and Partnership Assessment 48
Drivers, Restraints, and Trends—Total Pharmaceutical Contract Manufacturing Market 51
• Market Drivers 52
• Market Restraints 53
• Market Impact of Key Drivers and Restraints 54
Forecasts and Trends—Total Pharmaceutical Contract Manufacturing Market 55
• Market Engineering Measurements 56
• Forecast Assumptions 58
• Revenue Forecast 59
• Revenue Forecast Discussion 60
• Percent Revenue Forecast by Region 63
• Revenue Forecast by Region 64
• Key Market Trends 65

17. 17NC04-52
Contents (continued)
Section Slide Number
• Key Technology Trends 72
• Market Impact of Key Trends 76
• Venture Capital Trends in CMO 77
• Segment Lifecycle Analysis 78
End-User Analysis/Demand Analysis—Total Pharmaceutical Contract Manufacturing
Market
79
• End-user Survey Objectives 80
• End-user Survey Methodology 81
• Outsourcing Trend Analysis by Company Type 82
• Number of CMOs Companies Work With and by Company Type 83
• End-user Classification Based on CMO Use 84
• End-user Breakdown by Company Type 85
• Criteria for CMO Selection 86
• Top 5 Factors for CMO Selection 87
• Top 5 Factors for CMO Selection Discussion 88
• Stated Versus Unstated Importance of Selection Factors 89

18. 18NC04-52
Contents (continued)
Section Slide Number
• Stated Versus Unstated Importance of Selection Factors Discussion 90
• Extent of Outsourcing to CMOs by Service Areas 91
• Analysis of Outsourcing Budget Based on Product Revenue 92
• Outsourcing of Pharmaceutical Manufacturing Demand Forecast 93
• Industry Capacity Utilisation Forecast 94
• Industry Capacity Utilisation Forecast Discussion 95
Market Share and Competitive Analysis—Total Pharmaceutical Contract
Manufacturing Market
96
• Market Share 97
• Market Share Analysis 98
• CMO Breakdown by Finished Dose Segments 100
Solid Dose Formulations Segment Breakdown 130
• Solid Dose Formulations Segment Key Findings 131
• Market Engineering Measurements 132
• Revenue Forecast 133
• Revenue Forecast Discussion 134

19. 19NC04-52
Contents (continued)
Section Slide Number
Liquid and Semi-solid Dose Formulations Segment Breakdown 136
• Liquid and Semi-solid Dose Formulations Segment Key Findings 137
• Market Engineering Measurements 139
• Revenue Forecast 139
• Revenue Forecast Discussion 140
Injectable Dose Formulations Segment Breakdown 141
• Injectable Dose Formulations Segment Key Findings 142
• Market Engineering Measurements 143
• Revenue Forecast 144
• Revenue Forecast Discussion 145
United States Breakdown 147
• US Pharmaceutical Contract Manufacturing Market—Market Engineering
Measurements
148
• US Pharmaceutical Contract Manufacturing Market Revenue Forecast 149
• US Pharmaceutical Contract Manufacturing Market Revenue Forecast Discussion 150
• Solid Dose Formulations Segment Revenue Forecast 151

20. 20NC04-52
Contents (continued)
Section Slide Number
• Solid Dose Formulations Segment Revenue Forecast Discussion 152
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 153
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 154
• Injectable Dose Formulations Segment Revenue Forecast 155
• Injectable Dose Formulations Segment Revenue Forecast Discussion 156
• Pricing Analysis 157
• Market Analysis 158
• PESTLE Analysis 159
Europe Breakdown 160
• European Pharmaceutical Contract Manufacturing Market—Market Engineering
Measurements
161
• European Pharmaceutical Contract Manufacturing Market Revenue Forecast 162
• European Pharmaceutical Contract Manufacturing Market Revenue Forecast
Discussion
163
• Solid Dose Formulations Segment Revenue Forecast 164
• Solid Dose Formulations Segment Revenue Forecast Discussion 165

21. 21NC04-52
Contents (continued)
Section Slide Number
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 166
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 167
• Injectable Dose Formulations Segment Revenue Forecast 168
• Injectable Dose Formulations Segment Revenue Forecast Discussion 169
• Pricing Analysis 170
• Market Analysis 171
• PESTLE Analysis 172
United Kingdom Breakdown 173
• Solid Dose Formulations Segment Revenue Forecast 174
• Solid Dose Formulations Segment Revenue Forecast Discussion 175
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 176
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 177
• Injectable Dose Formulations Segment Revenue Forecast 178
• Injectable Dose Formulations Segment Revenue Forecast Discussion 179
Germany Breakdown 180
• Solid Dose Formulations Segment Revenue Forecast 181

22. 22NC04-52
Contents (continued)
Section Slide Number
• Solid Dose Formulations Segment Revenue Forecast Discussion 182
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 183
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 184
• Injectable Dose Formulations Segment Revenue Forecast 185
• Injectable Dose Formulations Segment Revenue Forecast Discussion 186
France Breakdown 187
• Solid Dose Formulations Segment Revenue Forecast 188
• Solid Dose Formulations Segment Revenue Forecast Discussion 189
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 190
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 191
• Injectable Dose Formulations Segment Revenue Forecast 192
• Injectable Dose Formulations Segment Revenue Forecast Discussion 193
Italy Breakdown 194
• Solid Dose Formulations Segment Revenue Forecast 195
• Solid Dose Formulations Segment Revenue Forecast Discussion 196

23. 23NC04-52
Contents (continued)
Section Slide Number
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 197
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 198
• Injectable Dose Formulations Segment Revenue Forecast 199
• Injectable Dose Formulations Segment Revenue Forecast Discussion 200
Spain Breakdown 201
• Solid Dose Formulations Segment Revenue Forecast 202
• Solid Dose Formulations Segment Revenue Forecast Discussion 203
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 204
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 205
• Injectable Dose Formulations Segment Revenue Forecast 206
• Injectable Dose Formulations Segment Revenue Forecast Discussion 207
Scandinavia Breakdown 208
• Solid Dose Formulations Segment Revenue Forecast 209
• Solid Dose Formulations Segment Revenue Forecast Discussion 210
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 211
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 212

24. 24NC04-52
Contents (continued)
Section Slide Number
• Injectable Dose Formulations Segment Revenue Forecast 213
• Injectable Dose Formulations Segment Revenue Forecast Discussion 214
Benelux Breakdown 215
• Solid Dose Formulations Segment Revenue Forecast 216
• Solid Dose Formulations Segment Revenue Forecast Discussion 217
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 218
• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 219
• Injectable Dose Formulations Segment Revenue Forecast 220
• Injectable Dose Formulations Segment Revenue Forecast Discussion 221
Key Companies to Watch 222
• Key Companies to Watch 223
• Catalent 224
• Patheon 227
• Aenova 230
• Famar 233
• Fareva 236

25. 25NC04-52
Contents (continued)
Section Slide Number
• Haupt Pharma AG 239
• Recipharm AB 242
• DPT Laboratories 245
• Aesica 248
• Baxter BioPharma Solutions 251
• Vetter Pharma 254
• Hospira One 2 One 257
• NextPharma Technologies 260
The Last Word 263
• The Last Word—Three Big Predictions 264
• The Last Word—Discussion 265
• Legal Disclaimer 268
Appendix 269
• Market Background 270
• Important Market Metrics 271
• Market Landscape and Pricing 272

26. 26NC04-52
Contents (continued)
Section Slide Number
• Drivers Explained 273
• Restraints Explained 278
• US Patent Expiration Timetable 282
• Europe Patent Expiration Timetable 284
• Decision Support Database—Total Healthcare Expenditure 291
• Decision Support Database—Public Healthcare Expenditure 293
• Decision Support Database—Private Healthcare Expenditure 295
• Additional Sources of Information on Contract Outsourcing Services 297
• List of Other Key Companies Included in this Research Service 298
• Market Engineering Methodology 299
• Learn More—Next Steps 300

27. 27NC04-52
List of Exhibits
Section Slide Number
Total Pharmaceutical Contract Manufacturing Market: Market Segmentation, Global, 2012 27
Total Pharmaceutical Contract Manufacturing Market: Market Engineering Measurements,
Global, 2012
29
Total Pharmaceutical Contract Manufacturing Market: Percent Sales Breakdown by
Segments, Global, 2012
40
Total Pharmaceutical Contract Manufacturing Market: Percent Sales Breakdown by
Manufacturing Process, Global, 2012
41
Total Pharmaceutical Contract Manufacturing Market: Percent Sales Breakdown by Patent
Exclusivity Status, Global, 2012
42
Total Pharmaceutical Contract Manufacturing Market: Percent Revenue Breakdown by
Geographic Region, Global, 2012
43
Total Pharmaceutical Contract Manufacturing Market: Market Outlook, Global, 2012 and
2022
44
Total Pharmaceutical Contract Manufacturing Market: Game-changing Strategies, Global,
2012
47
Total Pharmaceutical Contract Manufacturing Market: Market Outlook, Global, 2010–2012 50
Total Pharmaceutical Contract Manufacturing Market: Key Market Drivers, Global, 2013–
2017
52

28. 28NC04-52
List of Exhibits (continued)
Section Slide Number
Total Pharmaceutical Contract Manufacturing Market: Key Market Restraints, Global,
2013–2017
53
Total Pharmaceutical Contract Manufacturing Market: Impact of Key Drivers and
Restraints, Global, 2012
54
Total Pharmaceutical Contract Manufacturing Market: Market Engineering Measurements,
Global, 2012
57
Total Pharmaceutical Contract Manufacturing Market: Revenue Forecast, Global, 2009–2017 59
Total Pharmaceutical Contract Manufacturing Market: Percent Points Comparison with the US,
Global, 2012
61
Total Pharmaceutical Contract Manufacturing Market: Percent Points Manufacturing Cost
Comparison with the US, Global, 2012
62
Total Pharmaceutical Contract Manufacturing Market: Percent Points Labour Cost Comparison
with the US, Global, 2012
62
Total Pharmaceutical Contract Manufacturing Market: Percent Revenue Forecast by Region,
Global, 2009–2017
63
Total Pharmaceutical Contract Manufacturing Market: Revenue Forecast by Region, Global,
2009–2017
64
Total Pharmaceutical Market: Combined Prescription Sales for the Top 50 Pharmaceutical
Companies by Molecule Type, Global, 2012–2017
65

29. 29NC04-52
Section Slide Number
Total Pharmaceutical Market: Combined Prescription Sales for the Top 50 Pharmaceutical
Companies by Therapeutic Area, Global, 2012–2017
66
Pharmaceutical Contract Manufacturing Market: Percent of Combined Prescription Sales for Big
Pharmaceutical Companies by Molecule Type, Global, 2012–2017
67
Pharmaceutical Contract Manufacturing Market: Percent of Combined Prescription Sales for Mid-
sized Pharmaceutical Companies by Molecule Type, Global, 2012–2017
68
Total Pharmaceutical Contract Manufacturing Market: Percent Breakdown of Activities
Outsourced, Global, 2012
70
Total Pharmaceutical Contract Manufacturing Market: CAGRs of Segments Likely to Have
Higher Levels of Outsourcing, Global, 2012–2019
70
Total Pharmaceutical Contract Manufacturing Market: Market Impact of Key Trends, Global, 2012 76
Total Pharmaceutical Contract Manufacturing Market: Segment Lifecycle Analysis, Global, 2012 78
Total Pharmaceutical Contract Manufacturing Market: Percent Finished Dose Manufacturing
Outsourced by Company Type, Global, 2012
82
Total Pharmaceutical Contract Manufacturing Market: Percent Breakdown of Number of CMOs
Companies Work With, Global, 2012
83
Total Pharmaceutical Contract Manufacturing Market: Percent Breakdown of Number of CMOs
Companies Work With by Company Type, Global, 2012
83
List of Exhibits (continued)

30. 30NC04-52
List of Exhibits (continued)
Section Slide Number
Total Pharmaceutical Contract Manufacturing Market: End-user Percent Breakdown by CMO
Budget, Global, 2012
84
Total Pharmaceutical Contract Manufacturing Market: End-user Percent Breakdown by Company
Type, Global, 2012
85
Total Pharmaceutical Contract Manufacturing Market: Customer Utility Value of Various Factors
Involved in the Selection of a CMO, Global, 2012
86
Total Pharmaceutical Contract Manufacturing Market: Percent Breakdown of Top 5 Factors for
CMO Selection, Global, 2012
87
Total Pharmaceutical Contract Manufacturing Market: Percent Breakdown of Top 5 Factors for
CMO Selection by Company Type, Global, 2012
88
Total Pharmaceutical Contract Manufacturing Market: Extent of Outsourcing to CMOs by Service
Areas, Global, 2012
91
Total Pharmaceutical Contract Manufacturing Market: Extent of Outsourcing to CMOs by Service
Areas, Global, 2017
91
Total Pharmaceutical Contract Manufacturing Market: Percent Outsourcing Budget Allocation
Based on Product Revenue, Global, 2012
92
Total Pharmaceutical Contract Manufacturing Market: Outsourcing of Pharmaceutical
Manufacturing Demand Forecast, Global, 2012–2017
93
Total Pharmaceutical Contract Manufacturing Market: Industry Capacity Utilization Forecast,
Global, 2012–2017
94

31. 31NC04-52
List of Exhibits (continued)
Section Slide Number
Total Pharmaceutical Contract Manufacturing Market: CMO Market Share, Global, 2012 97
Total Pharmaceutical Contract Manufacturing Market: CMO Market Share Analysis, Global, 2012 98
Total Pharmaceutical Contract Manufacturing Market: CMO Breakdown by Finished Dose
Segments, Global, 2012
100
Solid Dose Formulations Segment: Percent Sales Breakdown by Sub-segments, Global, 2012 131
Solid Dose Formulations Segment: Market Engineering Measurements, Global, 2012 132
Solid Dose Formulations Segment: Revenue Forecast, Global, 2009–2017 133
Liquid and Semi-solid Dose Formulations Segment: Percent Sales Breakdown by Sub-segments,
Global, 2012
137
Liquid and Semi-solid Dose Formulations Segment: Market Engineering Measurements, Global,
2012
138
Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Global, 2009–2017 139
Injectable Dose Formulations Segment: Percent Sales Breakdown by Sub-segments, Global,
2012
142
Injectable Dose Formulations Segment: Market Engineering Measurements, Global, 2012 143
Injectable Dose Formulations Segment: Revenue Forecast, Global, 2009–2017 144

32. 32NC04-52
List of Exhibits (continued)
Section Slide Number
Pharmaceutical Contract Manufacturing Market: Market Engineering Measurements, US, 2012 148
Pharmaceutical Contract Manufacturing Market: Revenue Forecast, US, 2009–2017 149
Solid Dose Formulations Segment: Revenue Forecast, US, 2009–2017 151
Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, US, 2009–2017 153
Injectable Dose Formulations Segment: Revenue Forecast, US, 2009–2017 156
Pharmaceutical Contract Manufacturing Market: Pricing Analysis, US, 2012 157
Pharmaceutical Contract Manufacturing Market: PESTLE Analysis, US, 2012 159
Pharmaceutical Contract Manufacturing Market: Market Engineering Measurements, Europe,
2012
161
Pharmaceutical Contract Manufacturing Market: Revenue Forecast, Europe, 2009–2017 162
Solid Dose Formulations Segment: Revenue Forecast, Europe, 2009–2017 164
Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Europe, 2009–2017 166
Injectable Dose Formulations Segment: Revenue Forecast, Europe, 2009–2017 168
Pharmaceutical Contract Manufacturing Market: Pricing Analysis, Europe, 2012 170
Pharmaceutical Contract Manufacturing Market: PESTLE Analysis, Europe, 2012 172

33. 33NC04-52
List of Exhibits (continued)
Section Slide Number
Solid Dose Formulations Segment: Revenue Forecast, United Kingdom, 2009–2017 174
Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, United Kingdom, 2009–
2017
176
Injectable Dose Formulations Segment: Revenue Forecast, United Kingdom, 2009–2017 178
Solid Dose Formulations Segment: Revenue Forecast, Germany, 2009–2017 181
Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Germany, 2009–2017 183
Injectable Dose Formulations Segment: Revenue Forecast, Germany, 2009–2017 185
Solid Dose Formulations Segment: Revenue Forecast, France, 2009–2017 188
Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, France, 2009–2017 190
Injectable Dose Formulations Segment: Revenue Forecast, France, 2009–2017 192
Solid Dose Formulations Segment: Revenue Forecast, Italy, 2009–2017 195
Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Italy, 2009–2017 197
Injectable Dose Formulations Segment: Revenue Forecast, Italy, 2009–2017 199
Solid Dose Formulations Segment: Revenue Forecast, Spain, 2009–2017 202
Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Spain, 2009–2017 204

34. 34NC04-52
List of Exhibits (continued)
Section Slide Number
Injectable Dose Formulations Segment: Revenue Forecast, Spain, 2009–2017 206
Solid Dose Formulations Segment: Revenue Forecast, Scandinavia, 2009–2017 209
Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Scandinavia, 2009–2017 211
Injectable Dose Formulations Segment: Revenue Forecast, Scandinavia, 2009–2017 213
Solid Dose Formulations Segment: Revenue Forecast, Benelux, 2009–2017 216
Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Benelux, 2009–2017 218
Injectable Dose Formulations Segment: Revenue Forecast, Benelux, 2009–2017 220
Total Pharmaceutical Contract Manufacturing Market: Important Market Growth Metrics, Global,
2012
271
Total Pharmaceutical Contract Manufacturing Market: Client-wise Revenue Contribution to CMOs,
Global, 2012
274
Total Pharmaceutical Contract Manufacturing Market: VC Investment in Pharmaceutical/Biotech
Companies and CMOs, Global, 2000–2011
280
Total Pharmaceutical Contract Manufacturing Market: Key Blockbuster Drugs Losing Patent
Protection, US, 2012–2017
282
Total Pharmaceutical Contract Manufacturing Market: Key Blockbuster Drugs Losing Patent
Protection, Europe, 2010–2017
284

35. 35NC04-52
List of Exhibits (continued)
Section Slide Number
Decision Support Database: Total Healthcare Expenditure, Global, 2008-2018 291
Decision Support Database: Public Healthcare Expenditure, Global, 2008-2018 293
Decision Support Database: Private Healthcare Expenditure, Global, 2008-2018 295

36. 36NC04-52
For more information
Jennifer Carson
Healthcare & Life Sciences
(+1) 210.247.2450
jennifer.carson@frost.com